The Latest Breaking News on Pharma

Dive into the intriguing saga of unanticipated control failures at Moderna's magnate production plant, a juicy scoop exclusively unraveled by the meticulou...

Hundreds of thousands of older Americans could pay less for outpatient drug treatments beginning early next year

U.S. health officials grapple with inadequate inspection of overseas eyedrop factories, leading to recalls of potentially dangerous products.

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

Citius Pharmaceuticals (CTXR) has been making significant progress in its pipeline, garnering investors' attention. However, considering that CTXR is an unprofitable and pre-revenue business, is it worth investing now as the company prepares to report quarterly results? Keep reading.

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

‘He’s one of the few presidents that got almost everything right. He understood the proper role of the federal government under the Constitution,’ DeSantis says